Overview

An Open-Label Safety Study of A-101 Solution

Status:
Completed

Trial end date:
2016-10-01

Target enrollment:

Participant gender:

Summary

This is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face.

Phase:

Phase 3

Details

Lead Sponsor:

Aclaris Therapeutics, Inc.

Treatments:

Pharmaceutical Solutions